April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

CME Congresses .

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

CME Congresses .

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

CME Congresses .

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

CME Congresses .

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

CME Congresses .

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

CME Congresses .

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?

CME Congresses .

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?

March 16th- Belumosudil vs Best Available Therapy in cGVHD: Real-World Evidence That Matters

CME Congresses .

March 16th- Belumosudil vs Best Available Therapy in cGVHD: Real-World Evidence That Matters

March 12th- Beyond the webinar: Supportive Care in Chronic GVHD- Beyond Immunosuppression

CME Congresses .

March 12th- Beyond the webinar: Supportive Care in Chronic GVHD- Beyond Immunosuppression

March 9th- Dr. David Scott- Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology

CME Congresses .

March 9th- Dr. David Scott- Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology